AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On April 14, 2017, our board of directors approved (i) a
one-for-ten reverse split of our outstanding common stock and
(ii) a corresponding, proportional reduction in the number of our
authorized shares of common stock, each to become effective to
the filing of Articles of Amendment to our Articles of
Incorporation.
On April 21, 2017, we filed, with the Secretary of State of the
State of Washington, Articles of Amendment to our Articles of
Incorporation (the Charter Amendment) to (i)effect the
one-for-ten reverse split of our outstanding common stock and
(ii)reduce the authorized number of shares of our common stock
from 670,000,000 to 67,000,000 shares. The Charter Amendment will
be effective at 5:00 p.m. Eastern Time on April 24, 2017 (the
Effective Time).
The Charter Amendment provides that, at the Effective Time,
(a)every ten shares of our issued and outstanding common stock
will automatically be combined into one issued and outstanding
share of common stock, without any change in par value per share,
and (b)the number of authorized shares of common stock will be
reduced to 67,000,000 shares. As a result of the reverse stock
split, proportionate adjustments will be made to the per share
exercise price and/or the number of shares issuable upon the
exercise or vesting of all stock options and warrants issued by
us and outstanding immediately prior to the Effective Time, which
will result in a proportionate decrease in the number of shares
of our common stock reserved for issuance upon exercise or
vesting of such stock options and warrants, and, in the case of
stock options and warrants, a proportionate increase in the
exercise price of all such stock options and warrants. In
addition, the number of shares authorized for future grant under
our equity incentive/compensation plans immediately prior to the
Effective Time will be reduced proportionately.
Our common stock will begin trading on the NYSE MKT on a
split-adjusted basis when the market opens on April 25, 2017. The
new CUSIP number for the Companys common stock following the
reverse stock split is 03211P 301.
The foregoing summary of the Charter Amendment is qualified in
its entirety by reference to the Charter Amendment, which is
attached to this Current Report on Form 8-K as Exhibit 3.1 and is
incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
| 3.1 |
Articles of Amendment to Articles of Incorporation of AmpliPhi Biosciences Corporation |
|
About AmpliPhi Biosciences Corporation (NYSEMKT:APHB)
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01. AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Recent Trading Information
AmpliPhi Biosciences Corporation (NYSEMKT:APHB) closed its last trading session up +0.030 at 0.355 with shares trading hands.
